U.S. and international medical organizations recommend against testing children for genetic diseases that occur after adolescence and for which no prevention or treatment is available.
Clinical case and commentary on how physicians should respond when confronted by medication requests from parents of children with mood and concentration disorders.
Frank A. Chervenak, MD and Laurence B. McCullough, PhD
Clinical facts and physicians’ ethical obligations are critical in resolving disagreements between parents and physicians about resuscitation of an extremely premature infant.
Physicians should fully understand the ethical principles and professional standards involved in making decisions for the treatment of impaired newborns.
Two physicians offer commentaries about the use of prenatal predictive testing for a late-onset disease like Huntington's and question whether the pregnant woman should ultimately have the decisional autonomy to determine the quality of life of the unborn child.
Two physicians offer commentaries about the use of prenatal predictive testing for a late-onset disease like Huntington's and question whether the pregnant woman should ultimately have the decisional autonomy to determine the quality of life of the unborn child.
Physicians should seriously weigh the benefits and risks involved prior to discussing the possibility of genetic testing with a patient or referring them to a genetic counselor.
Physicians should understand and be sensitive to all of the issues that affect patients when they prescribe the tertogenic medication isotretinoin for treatment of acne vulgaris.
Anne-Marie Laberge, MD, MPH and Wylie Burke, MD, PhD
Two physicians examine the risks of testing minor children for late-onset genetic diseases when there is no current benefit and explain why several medical associations oppose the practice.